CSS LLC’s TG Therapeutics TGTX Stock Holding History

CSS LLC’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,000	Closed	-$95K	–	1221
2022 Q1	$95K	Sell	10,000 -10,800	-52%	-$125K	﹤0.01%	946
2021 Q4	$395K	Buy	+20,800	New	+$540K	0.01%	731

Other funds holding TGTX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS LLC's TGTX Position: Q4 2021 in Review

CSS LLC sold out of TG Therapeutics (TGTX) in Q4 2021, closing a stake of 7,550 shares — an estimated $196K sold.

CSS LLC first reported a position in TGTX in Q4 2020 and held it in 2 quarters. The position peaked at $311K in Q4 2020. 194 funds tracked by Wall St. Rank hold TGTX as of Q4 2021.

CSS LLC reported no remaining TG Therapeutics position as of Q4 2021 after selling out during the quarter.
CSS LLC sold 7,550 TG Therapeutics shares in Q4 2021, an estimated $196K.
CSS LLC first reported a position in TG Therapeutics in Q4 2020 and held it in 2 quarters.
CSS LLC's TG Therapeutics position peaked at $311K in Q4 2020.
194 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2021.

Based on CSS LLC's 13F filing for Q4 2021, filed 14 Feb 2022.